Johnson & Johnson (JNJ)
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.
JNJ Stock A Winner Right Now?
We believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
2 Unstoppable Stocks That Are Screaming Buys in August
Strong companies with profitable businesses and a path to future growth can drive investor returns over the long run. Johnson & Johnson is still working to resolve talc claims, but its business is doing extremely well, and its balance sheet can weather the storm.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson faces challenges related to a new law in the U.S. The company can find ways to navigate this problem. The stock remains a great pick for income seekers.
3 of the Best Long-Term Stocks to Buy Now and Hold Forever
Investors have long sought to maximize gains by timing the market – buying low and selling high.
J&J in talks with holdouts to $6.5 billion talc settlement
Johnson & Johnson said on Friday it is negotiating with plaintiffs' lawyers who have opposed the company's proposed settlement of lawsuits alleging its baby powder and other talc products caused cancer, seeking to eliminate holdouts to the deal.
Johnson & Johnson: The Dividend King Is Back
Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions. The company's robust financials, including a triple-A credit rating and significant cash reserves, position it well for sustained growth and reduced legal risks. Despite past underperformance, the company offers a reliable 3.1% dividend and a reasonable valuation, making it an attractive option for low-risk, long-term investors.
Johnson & Johnson: Don't Bet Against Double Compounding
JNJ bulls often praise its dividends - rightfully. However, the above-average yield and remarkable dividend record understate the attractiveness. Investors should focus on total shareholder returns, which include dividends but also other factors such as EPS growth and buybacks.
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.
